Disease · MONDO_0000430
Trials224
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 6 more are not shown, since the checks do not confirm them.
1 to 20 of 224
Download this page as JSON| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01777152 | ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas | Phase 3 | 452 | 2019-07-30 | Anaplastic Large-Cell Lymphoma, Non-Hodgkin Lymphoma, T-Cell Lymphoma | BRENTUXIMAB VEDOTIN, CYCLOPHOSPHAMIDE, DOXORUBICIN, PREDNISONE | Its record names the disease | ClinicalTrials.gov |
| NCT01482962 | Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma | Phase 3 | 271 | 2018-07-31 | Relapsed Peripheral T-Cell Lymphoma, Refractory Peripheral T-Cell Lymphoma | ALISERTIB, GEMCITABINE, PRALATREXATE, ROMIDEPSIN | Its record names the disease | ClinicalTrials.gov |
| NCT04105010 | Assessing An Oral Janus Kinase Inhibitor, AZD4205 as Monotherapy in Patients Who Have PTCL (JACKPOT8) | Phase 1/2 | 171 | 2025-04-04 | Relapsed or Refractory Peripheral T Cell Lymphoma | GOLIDOCITINIB | Its record names the disease | ClinicalTrials.gov |
| NCT04703192 | Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01) | Phase 2 | 155 | 2024-07-22 | Relapsed/Refractory Peripheral T-Cell Lymphoma, Adult T Cell Leukemia/Lymphoma | VALEMETOSTAT TOSYLATE | Its record names the disease | ClinicalTrials.gov |
| NCT02581631 | An Investigational Immuno-therapy Safety and Effectiveness Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin Lymphomas | Phase 1/2 | 145 | 2023-03-07 | Non-Hodgkin's Disease | BRENTUXIMAB VEDOTIN, NIVOLUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT00007345 | Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma | Phase 2 | 131 | 2016-02-12 | Cutaneous T Cell Lymphoma, Peripheral T Cell Lymphoma | ROMIDEPSIN | Its record names the disease | ClinicalTrials.gov |
| NCT01716806 | A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL) | Phase 2 | 131 | 2024-06-11 | Hodgkin Disease, Peripheral T Cell Lymphoma | BENDAMUSTINE, BRENTUXIMAB VEDOTIN, DACARBAZINE, NIVOLUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT04101331 | Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides | Phase 2 | 108 | 2023-06-05 | Peripheral T Cell Lymphoma, Transformed Mycosis Fungoides | ACIMTAMIG | Its record names the disease | ClinicalTrials.gov |
| NCT05011058 | An Open-Label Phase 2 Trial of Nanatinostat Plus Valganciclovir in Patients With EBV+ Relapsed/Refractory Lymphomas | Phase 2 | 102 | 2025-07-28 | Epstein-Barr Virus Associated Lymphoma, EBV-Positive DLBCL, NOS, EBV-Related Non-Hodgkin Lymphoma, EBV Related PTCL, NOS, EBV-Related Hodgkin Lymphoma, EBV-Related PTLD, EBV-Related Lymphoproliferative Disorder | NANATINOSTAT, VALGANCICLOVIR | Its record names the disease | ClinicalTrials.gov |
| NCT04213209 | Special Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion "Relapsed or Refractory CD30-positive Peripheral T Cell Lymphoma or Pediatric Hodgkin Lymphoma" | 95 | 2024-09-27 | Peripheral T Cell Lymphoma, Pediatric Hodgkin Lymphoma | BRENTUXIMAB VEDOTIN | Its record names the disease | ClinicalTrials.gov | |
| NCT03349333 | A Single Arm Study Evaluating the Efficacy and Safety of Pralatrexate in Subjects With Relapsed or Refractory PTCL | Phase 3 | 85 | 2019-09-12 | Refractory Peripheral T-Cell Lymphoma, Relapsed T-Cell Lymphoma | PRALATREXATE | Its record names the disease | ClinicalTrials.gov |
| NCT04569032 | A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression | Phase 2 | 82 | 2025-05-15 | Peripheral T-cell Lymphoma | BRENTUXIMAB VEDOTIN, CYCLOPHOSPHAMIDE, DOXORUBICIN, PREDNISONE | Its record names the disease | ClinicalTrials.gov |
| NCT01431209 | Ruxolitinib Phosphate to Treat Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin Lymphoma After Stem Cell Transplant | Phase 2 | 71 | 2021-06-24 | Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma | RUXOLITINIB PHOSPHATE | Its record names the disease | ClinicalTrials.gov |
| NCT03779113 | An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With Lymphoma | Phase 1 | 69 | 2026-02-18 | Non Hodgkin Lymphoma | SOVLEPLENIB | Its record names the disease | ClinicalTrials.gov |
| NCT02464228 | Investigation of Tipifarnib in Treatment of Subjects With Peripheral T-Cell Lymphoma (PTCL) That Have Not Responded to Standard Therapy | Phase 2 | 65 | 2024-06-26 | Relapsed or Refractory Peripheral T-Cell Lymphoma | TIPIFARNIB | Its record names the disease | ClinicalTrials.gov |
| NCT00697346 | Study of MLN8237 in Participants With Advanced Hematological Malignancies | Phase 1 | 58 | 2019-05-31 | B-cell Follicular Lymphoma, B-cell Marginal Zone Lymphoma, Diffuse Large B-cell Lymphoma, B-cell Mantle Cell Lymphoma, B-cell Small Lymphocytic Lymphoma, B-Cell Chronic Lymphocytic Leukemia, Multiple Myeloma, Waldenstrom's Macroglobulinemia, Noncutaneous Peripheral T-cell Lymphoma Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Enteropathy Associated T-cell Lymphoma, NK Lymphoma | ALISERTIB | Its record names the disease | ClinicalTrials.gov |
| NCT01998035 | Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies | Phase 1/2 | 58 | 2024-08-22 | Lymphoid Malignancies, Lymphoma, Hodgkin Lymphoma, Non-hodgkin Lymphoma | AZACITIDINE, ROMIDEPSIN | Its record names the disease | ClinicalTrials.gov |
| NCT03769181 | A Study of Isatuximab-based Therapy in Participants With Lymphoma | Phase 1/2 | 58 | 2023-10-17 | Lymphoma | CEMIPLIMAB, ISATUXIMAB | Its record names the disease | ClinicalTrials.gov |
| NCT00542919 | A Study for Patients With Non-Hodgkin's Lymphomas | Phase 2 | 57 | 2020-10-19 | T-Cell Lymphoma, B-Cell Lymphoma | ENZASTAURIN | Its record names the disease | ClinicalTrials.gov |
| NCT00290433 | Efficacy of the HCVIDDOXIL Regimen in Patients With Newly Diagnosed Peripheral T-Cell Lymphoma | Phase 2 | 55 | 2020-09-23 | Lymphoma | CYCLOPHOSPHAMIDE, CYTARABINE, DEXAMETHASONE, DOXORUBICIN, FILGRASTIM, MESNA, METHOTREXATE, VINCRISTINE | Its record names the disease | ClinicalTrials.gov |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0000430/trials